STOCK TITAN
  1. Home
  2. Sec-filings
  3. CCCC
  4. [Form 4] C4 Therapeutics, Inc. Insider Trading Activity

C4 Therapeutics (CCCC) CEO receives 700,000 RSU equity award

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

C4 Therapeutics, Inc. reported multiple equity transactions by President & CEO Andrew Hirsch. On February 13, 2026, he received 700,000 restricted stock units (RSUs). According to the disclosure, 350,000 RSUs vest in three equal annual installments beginning on February 13, 2027, and 350,000 RSUs vest in full on February 13, 2029, subject to potential acceleration if certain performance milestones are achieved.

On February 14 and 15, 2026, previously granted RSUs vested, resulting in acquisitions of common stock through derivative exercises and conversions. In connection with these vestings, the company withheld 39,154 and 9,057 shares of common stock at $1.89 per share to cover tax withholding obligations. The filing states these withheld shares do not represent sales by Hirsch. After these transactions, he continued to hold over one million shares directly.

Positive

  • None.

Negative

  • None.
Insider Hirsch Andrew
Role President & CEO
Type Security Shares Price Value
Exercise Common Stock 20,400 $0.00 --
Tax Withholding Common Stock 9,057 $1.89 $17K
Exercise Common Stock 81,725 $0.00 --
Tax Withholding Common Stock 39,154 $1.89 $74K
Grant/Award Common Stock 700,000 $0.00 --
Holdings After Transaction: Common Stock — 1,083,991 shares (Direct)
Footnotes (1)
  1. Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 350,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 350,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones. Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 15, 2024 and February 18, 2025. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hirsch Andrew
(Last) (First) (Middle)
C/O C4 THERAPEUTICS, INC.
490 ARSENAL WAY #120
(Street)
WATERTOWN MA 02472
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
C4 Therapeutics, Inc. [ CCCC ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President & CEO
3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/13/2026 A 700,000(1) A $0 1,123,145 D
Common Stock 02/14/2026 M(2) V 81,725 A $0 1,123,145 D
Common Stock 02/14/2026 F(3) 39,154 D $1.89 1,083,991 D
Common Stock 02/15/2026 M(2) V 20,400 A $0 1,083,991 D
Common Stock 02/15/2026 F(3) 9,057 D $1.89 1,074,934 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest as follows: (i) 350,000 RSUs shall vest in three equal annual installments following the grant date, with the first installment vesting on February 13, 2027, and (ii) 350,000 RSUs shall vest in full on February 13, 2029, subject to potential acceleration upon achievement of certain performance milestones.
2. Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of RSUs. The grants of RSUs were initially reported in Table I of the Forms 4 filed by the Reporting Person on February 15, 2023, February 15, 2024 and February 18, 2025.
3. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Shagha Russell, Attorney-in-Fact 02/18/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did C4 Therapeutics (CCCC) CEO Andrew Hirsch receive in this Form 4 filing?

Andrew Hirsch received a grant of 700,000 restricted stock units (RSUs). Half vest in three equal annual installments starting February 13, 2027, and half vest on February 13, 2029, subject to performance milestones, aligning his compensation with long-term company performance.

How do the 700,000 RSUs for C4 Therapeutics (CCCC) CEO vest over time?

The 700,000 RSUs vest in two parts. 350,000 RSUs vest in three equal annual installments beginning February 13, 2027. The remaining 350,000 RSUs vest in full on February 13, 2029, contingent on achieving specified performance milestones.

Were any of C4 Therapeutics (CCCC) CEO Andrew Hirsch’s shares sold in the market?

The filing describes shares withheld by C4 Therapeutics to satisfy tax obligations upon RSU vesting. It explicitly states these withheld shares do not represent a sale by Andrew Hirsch, indicating no open-market sales in these reported transactions.

What other equity activity did C4 Therapeutics (CCCC) report for its CEO?

On February 14 and 15, 2026, previously disclosed RSU awards vested, leading to acquisitions of common stock through derivative exercises/conversions. At the same time, C4 Therapeutics withheld shares at $1.89 per share to cover associated tax withholding obligations.

How many C4 Therapeutics (CCCC) shares does CEO Andrew Hirsch hold after these transactions?

After the reported grants, vestings, and tax-withholding dispositions, Andrew Hirsch directly held 1,074,934 shares of C4 Therapeutics common stock. This reflects his remaining ownership following the company’s withholding of shares to satisfy tax obligations tied to RSU vesting.

What do the F-coded transactions mean in C4 Therapeutics (CCCC) CEO’s Form 4?

The F-coded transactions are described as payment of tax liability by delivering securities. C4 Therapeutics withheld 39,154 and 9,057 shares at $1.89 per share to cover taxes on vested RSUs, and these are not classified as sales by the CEO.